成人异基因造血干细胞移植受者他克莫司群体药代动力学模型助力精准给药
该研究基于290例成人allo-HCT受者的906个PK样本建立口服他克莫司二室popPK模型,发现CYP3A5代谢型显著影响清除率,蒙特卡洛模拟显示模型衍生给药策略使D0谷浓度达标概率从37%提升至76%。
要点
- CYP3A5中间/正常代谢者较慢代谢者需约100%剂量增加。
- 现行按体重给药方案D0达标概率仅37%,模型衍生策略可达76%。
- 建议结合CYP3A5代谢型与预处理强度制定起始剂量。
核心结论
- 现行按体重给药范式不足,基于CYP3A5代谢型和预处理强度的模型衍生给药策略可提高D0目标浓度达标率。
研究设计与样本
- 基于UNC医疗中心两项PK研究的290例成人allo-HCT受者、906个PK样本,建立口服他克莫司二室popPK模型并进行蒙特卡洛模拟。
主要发现
- 70kg接受减低强度预处理者,CYP3A5慢代谢者表观清除率典型值为0.33 L/h/kg,中间/正常代谢者为0.70 L/h/kg。
- 现行UNC体重给药、CPIC推荐和模型衍生策略下,群体平均D0谷浓度处于UNC目标范围5-10 ng/mL的概率分别为37%、45%和76%。
- 预测CYP3A5中间/正常代谢者需较慢代谢者剂量增加100%。
关键数值与推荐
- UNC机构目标谷浓度范围为5-10 ng/mL。
- CYP3A5慢代谢者表观清除率典型值0.33 L/h/kg,中间/正常代谢者0.70 L/h/kg(70kg,减低强度预处理)。
- 模型衍生策略D0达标概率76%,现行体重给药37%,CPIC策略45%。
临床怎么用
- 成人allo-HCT受者起始他克莫司剂量应参考CYP3A5代谢型及预处理强度,而非仅按体重计算。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tacrolimus is a cornerstone of acute graft-versus-host disease (aGVHD) prophylaxis in allogeneic hematopoietic cell transplant (allo-HCT) recipients. However, a narrow therapeutic index and high interindividual variability in pharmacokinetics (PK) make starting dose selection a major challenge in clinical practice. METHODS: Data from two PK studies conducted at the University of North Carolina Medical Center (UNCMC) were used to develop an oral tacrolimus population pharmacokinetic (popPK) model specific to adult allo-HCT recipients. Monte Carlo simulations were performed to compare the likelihood of achieving the UNCMC institutional target trough concentration range (ITR) (5-10 ng/mL) on the day of transplant (D0) under the current institutional dosing protocol, dosing recommendations from the Clinical Pharmacogenetics Implementation Consortium (CPIC), and model-derived dosing recommendations. RESULTS: In total, 290 allo-HCT recipients contributed a total of 906 PK samples to the final analysis. A two-compartment popPK model adequately described the PK data. Population typical values of apparent clearance (TVCL/F) for 70 kg individuals receiving reduced intensity conditioning were 0.33 L/h/kg for CYP3A5 poor metabolizers (PMs) and 0.70 L/h/kg for intermediate and normal metabolizers (IMs and NMs). The probability of the population-level average D0 trough concentration being within the UNCMC ITR under the current UNCMC weight-based dosing protocol, CPIC-based, and model-derived dosing strategies were estimated to be 37%, 45%, and 76%, respectively. CYP3A5 IMs and NMs were predicted to require a 100% dose increase relative to CYP3A5 PMs. CONCLUSIONS: We propose a new oral tacrolimus dosing strategy for adult allo-HCT recipients, which suggests the current weight-based dosing paradigm is insufficient. This new strategy includes CYP3A5 metabolizer phenotypes and conditioning regimen intensity, and could increase the percentage of allo-HCT recipients achieving target concentrations on D0. CLINICAL TRIAL REGISTRATION NUMBER: Clinicaltrials.gov NCT04645667.
引用
- Dunlap TC, Zhu J, Weiner DL, et al. A Tacrolimus Population Pharmacokinetic Model for Adult Allogeneic Hematopoietic Cell Transplant Recipients Provides Clinical Opportunities for Precision Dosing. Clin Pharmacokinet. 2025. PMID: 40794300. doi:10.1007/s40262-025-01529-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。